← Eichor
Study identifier: NCT04305548 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Condition: Mesenchymal Chondrosarcoma  ·  Sponsor: Italian Sarcoma Group

PhasePhase 2
Planned participants16
Who can joinAll sexes, 16 Years to no upper limit
Healthy volunteersNo

About this study

Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)

This description comes directly from the study's public registry record.

Talk to the study team

Silvia Stacchiotti, MD  ·  39022390  ·  silvia.stacchiotti@istitutotumori.mi.it

Always discuss trial participation with your own doctor first.

Locations (7)

Nuovo Ospedale di PratoPrato, Firenze, ItalyRecruiting
Policlinico Universitario Campus BiomedicoRoma, RM, ItalyNot Yet Recruiting
Fondazione del Piemonte per l'Oncologia IRCC CandioloCandiolo, Torino, ItalyRecruiting
Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal TumorsBologna, ItalyRecruiting
Fondazione IRCSS Istituto Nazionale dei TumoriMilan, ItalyRecruiting
Ospedale GiacconePalermo, ItalyRecruiting
Istituti Fisioterapici Ospitalieri - Ospedale Regina ElenaRoma, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04305548